Psyence Biomedical Ltd. (NASDAQ:PBM – Get Free Report) was the target of a significant increase in short interest in the month of October. As of October 15th, there was short interest totalling 605,600 shares, an increase of 181.5% from the September 30th total of 215,100 shares. Currently, 6.5% of the shares of the company are sold short. Based on an average daily volume of 6,080,000 shares, the short-interest ratio is presently 0.1 days.
Hedge Funds Weigh In On Psyence Biomedical
A hedge fund recently bought a new stake in Psyence Biomedical stock. Virtu Financial LLC bought a new position in shares of Psyence Biomedical Ltd. (NASDAQ:PBM – Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 26,419 shares of the company’s stock, valued at approximately $30,000. Virtu Financial LLC owned approximately 0.30% of Psyence Biomedical at the end of the most recent reporting period. Institutional investors and hedge funds own 77.44% of the company’s stock.
Psyence Biomedical Price Performance
Shares of NASDAQ PBM opened at $0.10 on Monday. The stock has a fifty day simple moving average of $0.21 and a two-hundred day simple moving average of $0.49. Psyence Biomedical has a 1-year low of $0.08 and a 1-year high of $4.31.
About Psyence Biomedical
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company’s lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care.
Featured Stories
- Five stocks we like better than Psyence Biomedical
- Investing in Travel Stocks Benefits
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- What Makes a Stock a Good Dividend Stock?
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Comparing and Trading High PE Ratio Stocks
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Psyence Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Psyence Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.